Fenbendazole for Lung Cancer: The Joe Tippens Story vs. the Science
Joe Tippens claimed fenbendazole cured his stage 4 lung cancer. He was also on immunotherapy. Here is what the preclinical data actually shows for fenbendazole and lung cancer.
🔶 Grade C: Preclinical OnlyThe Bottom Line
Fenbendazole's association with lung cancer comes entirely from the Joe Tippens story: a stage 4 small cell lung cancer patient who claimed fenbendazole cured him in 2019. The viral story drove millions of searches for "fenbendazole lung cancer." Here's what the science actually shows.
The Joe Tippens Lung Cancer Case
Joe Tippens was diagnosed with stage 4 small cell lung cancer (SCLC) with metastases to the liver, neck, and bones. He was enrolled in a clinical trial for an experimental immunotherapy drug (a PD-1 checkpoint inhibitor). He added fenbendazole to his regimen after a veterinarian friend's suggestion. He reported complete remission.
The problem: Checkpoint immunotherapy can cause dramatic complete responses in lung cancer. This is literally what pembrolizumab (Keytruda) and nivolumab (Opdivo) were designed to do, and both are now standard first-line treatments for SCLC and NSCLC. Attributing Tippens' remission to fenbendazole rather than the immunotherapy he was simultaneously receiving is speculation, not evidence.
Preclinical Data for Lung Cancer
The original fenbendazole cancer paper (Duan et al., Nature Scientific Reports 2018) used A549 lung adenocarcinoma cells as one of its primary models:
- Fenbendazole destabilized microtubules in A549 cells at concentrations of 1-10 μM
- Induced G2/M cell cycle arrest and apoptosis
- p53 stabilization was observed (lung cancers with wild-type p53 may be more responsive)
- A 2025 animal study showed synergistic effects of fenbendazole + DCA in mice with A549 lung cancer xenografts
However: These are cell line and animal model results. No human clinical trial of fenbendazole in lung cancer has ever been conducted or even registered.
The Liver Toxicity Warning
The first published case of fenbendazole-induced liver injury was in a lung cancer patient. An 80-year-old woman with advanced NSCLC on pembrolizumab developed severe liver injury after self-administering fenbendazole based on social media (Yamaguchi et al., Case Reports in Oncology 2021). The liver damage was attributed to fenbendazole after structured causality assessment.
What Actually Works for Lung Cancer (Evidence-Based)
- Immunotherapy (PD-1/PD-L1 inhibitors): Pembrolizumab, nivolumab, atezolizumab. These are what likely cured Joe Tippens.
- High-dose IV vitamin C: Human trial data exists as a chemo adjunct
- Mebendazole: The human-approved benzimidazole with actual trial data
- Atovaquone: PET-CT confirmed tumor reoxygenation in NSCLC patients
Our Assessment
There is no human evidence that fenbendazole treats lung cancer. The Joe Tippens story is not evidence; it's an anecdote confounded by concurrent immunotherapy. The preclinical data in lung cancer cell lines exists but has not progressed to human trials. If you have lung cancer and are interested in repurposed drugs, discuss mebendazole or ivermectin (which has an active human trial) with your oncologist. Read our full fenbendazole review for the complete evidence breakdown.
Sources
- Nature Scientific Reports 2018;8:11926: Fenbendazole in A549 lung cancer cells nature.com
- Case Reports in Oncology 2021;14:886-91: Fenbendazole liver injury in NSCLC patient karger.com
- Translational Lung Cancer Research 2025: Fenbendazole + DCA synergy in A549 xenografts
Related Research
Medical Disclaimer: This is a research review, not medical advice. Always consult with qualified healthcare professionals before making any changes to your health regimen.
How we grade evidence: Grade A = Phase II+ RCT with positive signal. Grade B = Phase I/II or strong epidemiology. Grade C = Preclinical only. Debunked = Retracted or disproven. Full methodology →